Loading…
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy. However, our prior study revealed challenges in CAR-NK cells targeting CD19 antigens, as they failed to eliminate CD19 Raji cells in N...
Saved in:
Published in: | Journal of translational medicine 2024-03, Vol.22 (1), p.274-15, Article 274 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c564t-4270fffa09f8d7ccab27b861589ee47d5a577ee1d5ffa2b1d348589c41b4f33a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c564t-4270fffa09f8d7ccab27b861589ee47d5a577ee1d5ffa2b1d348589c41b4f33a3 |
container_end_page | 15 |
container_issue | 1 |
container_start_page | 274 |
container_title | Journal of translational medicine |
container_volume | 22 |
creator | Yang, Na Zhang, Caili Zhang, Yingchun Fan, Yuting Zhang, Jing Lin, Xiaojin Guo, Ting Gu, Yangzuo Wu, Jieheng Gao, Jianmei Zhao, Xing He, Zhixu |
description | Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy. However, our prior study revealed challenges in CAR-NK cells targeting CD19 antigens, as they failed to eliminate CD19
Raji cells in NSG tumor-bearing mice, noting down-regulation or loss of CD19 antigen expression in some Raji cells. In response, this study aims to enhance CD19 CAR-NK cell efficacy and mitigate the risk of tumor recurrence due to target antigen escape by developing CD19 and CD20 (CD19/CD20) dual-targeted CAR-NK cells.
Initially, mRNA encoding anti-CD19 CARs (FMC63 scFv-CD8α-4-1BB-CD3ζ) and anti-CD20 CARs (LEU16 scFv-CD8α-4-1BB-CD3ζ) was constructed via in vitro transcription. Subsequently, CD19/CD20 dual-targeted CAR-NK cells were generated through simultaneous electrotransfection of CD19/CD20 CAR mRNA into umbilical cord blood-derived NK cells (UCB-NK).
Following co-electroporation, the percentage of dual-CAR expression on NK cells was 86.4% ± 1.83%, as determined by flow cytometry. CAR expression was detectable at 8 h post-electric transfer, peaked at 24 h, and remained detectable at 96 h. CD19/CD20 dual-targeted CAR-NK cells exhibited increased specific cytotoxicity against acute lymphoblastic leukemia (ALL) cell lines (BALL-1: CD19
CD20
, REH: CD19
CD20
, Jurkat: CD19
CD20
) compared to UCB-NK, CD19 CAR-NK, and CD20 CAR-NK cells. Moreover, CD19/CD20 dual-targeted CAR-NK cells released elevated levels of perforin, IFN-γ, and IL-15. Multiple activation markers such as CD69 and cytotoxic substances were highly expressed.
The creation of CD19/CD20 dual-targeted CAR-NK cells addressed the risk of tumor escape due to antigen heterogeneity in ALL, offering efficient and safe 'off-the-shelf' cell products. These cells demonstrate efficacy in targeting CD20 and/or CD19 antigens in ALL, laying an experimental foundation for their application in ALL treatment. |
doi_str_mv | 10.1186/s12967-024-04990-6 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e9313db57b0742fe91ef8d45a640c2e7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A786245159</galeid><doaj_id>oai_doaj_org_article_e9313db57b0742fe91ef8d45a640c2e7</doaj_id><sourcerecordid>A786245159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c564t-4270fffa09f8d7ccab27b861589ee47d5a577ee1d5ffa2b1d348589c41b4f33a3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEoqXwBzigSFy4pLUTf55QteWjUiUucLYcZ5L1NrEX26m6_4MfjHdTShchH2zNPPOOPX6L4i1G5xgLdhFxLRmvUE0qRKREFXtWnGLCZUUFZ8-fnE-KVzFuUCYpkS-Lk0YQTgUmp8Wv1RWWF6urGpXdrMcq6TBAgq40aztBsKbULtkBXBnAwDb5UIEbrAMIGXI6zUGP5a0dRwilgXGMJdyvbWtTaadt8Hd7qV3yyd9bY9Ou1IO2LqZSmzlBOe6m7dq3o44ptxphvoXJ6tfFi16PEd487GfFj8-fvq--VjffvlyvLm8qQxlJFak56vteI9mLjhuj25q3gmEqJADhHdWUcwDc0QzVLe4aInLOENySvml0c1ZcL7qd1xu1DXbSYae8tuoQ8GFQOuSLjaBANrjpWspbxEndg8SQmxKqGUGmBp61Pi5a27mdoDPgUp7Mkehxxtm1Gvydwkg2VDKcFT48KAT_c4aY1GTjfqTagZ-jqiVlTPAFff8PuvFzcHlWB0qIBlH6lxp0foF1vc-NzV5UXXLBshkwlZk6_w-VV5e_wngHvc3xo4J6KTDBxxigf3wkRmpvTLUYU2W7qYMxFctF756O57HkjxOb31cV4Ng</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956883055</pqid></control><display><type>article</type><title>CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia</title><source>PubMed (Medline)</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Yang, Na ; Zhang, Caili ; Zhang, Yingchun ; Fan, Yuting ; Zhang, Jing ; Lin, Xiaojin ; Guo, Ting ; Gu, Yangzuo ; Wu, Jieheng ; Gao, Jianmei ; Zhao, Xing ; He, Zhixu</creator><creatorcontrib>Yang, Na ; Zhang, Caili ; Zhang, Yingchun ; Fan, Yuting ; Zhang, Jing ; Lin, Xiaojin ; Guo, Ting ; Gu, Yangzuo ; Wu, Jieheng ; Gao, Jianmei ; Zhao, Xing ; He, Zhixu</creatorcontrib><description>Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy. However, our prior study revealed challenges in CAR-NK cells targeting CD19 antigens, as they failed to eliminate CD19
Raji cells in NSG tumor-bearing mice, noting down-regulation or loss of CD19 antigen expression in some Raji cells. In response, this study aims to enhance CD19 CAR-NK cell efficacy and mitigate the risk of tumor recurrence due to target antigen escape by developing CD19 and CD20 (CD19/CD20) dual-targeted CAR-NK cells.
Initially, mRNA encoding anti-CD19 CARs (FMC63 scFv-CD8α-4-1BB-CD3ζ) and anti-CD20 CARs (LEU16 scFv-CD8α-4-1BB-CD3ζ) was constructed via in vitro transcription. Subsequently, CD19/CD20 dual-targeted CAR-NK cells were generated through simultaneous electrotransfection of CD19/CD20 CAR mRNA into umbilical cord blood-derived NK cells (UCB-NK).
Following co-electroporation, the percentage of dual-CAR expression on NK cells was 86.4% ± 1.83%, as determined by flow cytometry. CAR expression was detectable at 8 h post-electric transfer, peaked at 24 h, and remained detectable at 96 h. CD19/CD20 dual-targeted CAR-NK cells exhibited increased specific cytotoxicity against acute lymphoblastic leukemia (ALL) cell lines (BALL-1: CD19
CD20
, REH: CD19
CD20
, Jurkat: CD19
CD20
) compared to UCB-NK, CD19 CAR-NK, and CD20 CAR-NK cells. Moreover, CD19/CD20 dual-targeted CAR-NK cells released elevated levels of perforin, IFN-γ, and IL-15. Multiple activation markers such as CD69 and cytotoxic substances were highly expressed.
The creation of CD19/CD20 dual-targeted CAR-NK cells addressed the risk of tumor escape due to antigen heterogeneity in ALL, offering efficient and safe 'off-the-shelf' cell products. These cells demonstrate efficacy in targeting CD20 and/or CD19 antigens in ALL, laying an experimental foundation for their application in ALL treatment.</description><identifier>ISSN: 1479-5876</identifier><identifier>EISSN: 1479-5876</identifier><identifier>DOI: 10.1186/s12967-024-04990-6</identifier><identifier>PMID: 38475814</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acute lymphoblastic leukemia ; Acute lymphocytic leukemia ; Animals ; Antigens ; Antigens, CD19 - genetics ; Antigens, CD19 - metabolism ; CD19 antigen ; CD20 antigen ; CD69 antigen ; Cell Line, Tumor ; Cell therapy ; Cells ; Chimeric antigen receptor ; Chimeric antigen receptors ; Cloning ; Cord blood ; Cytotoxicity ; Cytotoxicity, Immunologic - genetics ; Diseases ; Down-regulation ; Dual targets ; Electroporation ; Flow cytometry ; Graft versus host disease ; Immunotherapy, Adoptive ; Killer Cells, Natural ; Leukemia ; Lymphatic leukemia ; Lymphocytes ; Lymphocytes T ; Lymphoma ; Medical prognosis ; Mice ; mRNA ; Natural killer cells ; Perforin ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism ; Quantitative analysis ; Receptors, Chimeric Antigen - metabolism ; Relapse ; Remission (Medicine) ; RNA ; RNA polymerase ; RNA, Messenger - metabolism ; Tumor cell lines ; Tumors ; Umbilical cord ; γ-Interferon</subject><ispartof>Journal of translational medicine, 2024-03, Vol.22 (1), p.274-15, Article 274</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c564t-4270fffa09f8d7ccab27b861589ee47d5a577ee1d5ffa2b1d348589c41b4f33a3</citedby><cites>FETCH-LOGICAL-c564t-4270fffa09f8d7ccab27b861589ee47d5a577ee1d5ffa2b1d348589c41b4f33a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10935961/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2956883055?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38475814$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Na</creatorcontrib><creatorcontrib>Zhang, Caili</creatorcontrib><creatorcontrib>Zhang, Yingchun</creatorcontrib><creatorcontrib>Fan, Yuting</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Lin, Xiaojin</creatorcontrib><creatorcontrib>Guo, Ting</creatorcontrib><creatorcontrib>Gu, Yangzuo</creatorcontrib><creatorcontrib>Wu, Jieheng</creatorcontrib><creatorcontrib>Gao, Jianmei</creatorcontrib><creatorcontrib>Zhao, Xing</creatorcontrib><creatorcontrib>He, Zhixu</creatorcontrib><title>CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia</title><title>Journal of translational medicine</title><addtitle>J Transl Med</addtitle><description>Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy. However, our prior study revealed challenges in CAR-NK cells targeting CD19 antigens, as they failed to eliminate CD19
Raji cells in NSG tumor-bearing mice, noting down-regulation or loss of CD19 antigen expression in some Raji cells. In response, this study aims to enhance CD19 CAR-NK cell efficacy and mitigate the risk of tumor recurrence due to target antigen escape by developing CD19 and CD20 (CD19/CD20) dual-targeted CAR-NK cells.
Initially, mRNA encoding anti-CD19 CARs (FMC63 scFv-CD8α-4-1BB-CD3ζ) and anti-CD20 CARs (LEU16 scFv-CD8α-4-1BB-CD3ζ) was constructed via in vitro transcription. Subsequently, CD19/CD20 dual-targeted CAR-NK cells were generated through simultaneous electrotransfection of CD19/CD20 CAR mRNA into umbilical cord blood-derived NK cells (UCB-NK).
Following co-electroporation, the percentage of dual-CAR expression on NK cells was 86.4% ± 1.83%, as determined by flow cytometry. CAR expression was detectable at 8 h post-electric transfer, peaked at 24 h, and remained detectable at 96 h. CD19/CD20 dual-targeted CAR-NK cells exhibited increased specific cytotoxicity against acute lymphoblastic leukemia (ALL) cell lines (BALL-1: CD19
CD20
, REH: CD19
CD20
, Jurkat: CD19
CD20
) compared to UCB-NK, CD19 CAR-NK, and CD20 CAR-NK cells. Moreover, CD19/CD20 dual-targeted CAR-NK cells released elevated levels of perforin, IFN-γ, and IL-15. Multiple activation markers such as CD69 and cytotoxic substances were highly expressed.
The creation of CD19/CD20 dual-targeted CAR-NK cells addressed the risk of tumor escape due to antigen heterogeneity in ALL, offering efficient and safe 'off-the-shelf' cell products. These cells demonstrate efficacy in targeting CD20 and/or CD19 antigens in ALL, laying an experimental foundation for their application in ALL treatment.</description><subject>Acute lymphoblastic leukemia</subject><subject>Acute lymphocytic leukemia</subject><subject>Animals</subject><subject>Antigens</subject><subject>Antigens, CD19 - genetics</subject><subject>Antigens, CD19 - metabolism</subject><subject>CD19 antigen</subject><subject>CD20 antigen</subject><subject>CD69 antigen</subject><subject>Cell Line, Tumor</subject><subject>Cell therapy</subject><subject>Cells</subject><subject>Chimeric antigen receptor</subject><subject>Chimeric antigen receptors</subject><subject>Cloning</subject><subject>Cord blood</subject><subject>Cytotoxicity</subject><subject>Cytotoxicity, Immunologic - genetics</subject><subject>Diseases</subject><subject>Down-regulation</subject><subject>Dual targets</subject><subject>Electroporation</subject><subject>Flow cytometry</subject><subject>Graft versus host disease</subject><subject>Immunotherapy, Adoptive</subject><subject>Killer Cells, Natural</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Mice</subject><subject>mRNA</subject><subject>Natural killer cells</subject><subject>Perforin</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</subject><subject>Quantitative analysis</subject><subject>Receptors, Chimeric Antigen - metabolism</subject><subject>Relapse</subject><subject>Remission (Medicine)</subject><subject>RNA</subject><subject>RNA polymerase</subject><subject>RNA, Messenger - metabolism</subject><subject>Tumor cell lines</subject><subject>Tumors</subject><subject>Umbilical cord</subject><subject>γ-Interferon</subject><issn>1479-5876</issn><issn>1479-5876</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1v1DAQhiMEoqXwBzigSFy4pLUTf55QteWjUiUucLYcZ5L1NrEX26m6_4MfjHdTShchH2zNPPOOPX6L4i1G5xgLdhFxLRmvUE0qRKREFXtWnGLCZUUFZ8-fnE-KVzFuUCYpkS-Lk0YQTgUmp8Wv1RWWF6urGpXdrMcq6TBAgq40aztBsKbULtkBXBnAwDb5UIEbrAMIGXI6zUGP5a0dRwilgXGMJdyvbWtTaadt8Hd7qV3yyd9bY9Ou1IO2LqZSmzlBOe6m7dq3o44ptxphvoXJ6tfFi16PEd487GfFj8-fvq--VjffvlyvLm8qQxlJFak56vteI9mLjhuj25q3gmEqJADhHdWUcwDc0QzVLe4aInLOENySvml0c1ZcL7qd1xu1DXbSYae8tuoQ8GFQOuSLjaBANrjpWspbxEndg8SQmxKqGUGmBp61Pi5a27mdoDPgUp7Mkehxxtm1Gvydwkg2VDKcFT48KAT_c4aY1GTjfqTagZ-jqiVlTPAFff8PuvFzcHlWB0qIBlH6lxp0foF1vc-NzV5UXXLBshkwlZk6_w-VV5e_wngHvc3xo4J6KTDBxxigf3wkRmpvTLUYU2W7qYMxFctF756O57HkjxOb31cV4Ng</recordid><startdate>20240313</startdate><enddate>20240313</enddate><creator>Yang, Na</creator><creator>Zhang, Caili</creator><creator>Zhang, Yingchun</creator><creator>Fan, Yuting</creator><creator>Zhang, Jing</creator><creator>Lin, Xiaojin</creator><creator>Guo, Ting</creator><creator>Gu, Yangzuo</creator><creator>Wu, Jieheng</creator><creator>Gao, Jianmei</creator><creator>Zhao, Xing</creator><creator>He, Zhixu</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240313</creationdate><title>CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia</title><author>Yang, Na ; Zhang, Caili ; Zhang, Yingchun ; Fan, Yuting ; Zhang, Jing ; Lin, Xiaojin ; Guo, Ting ; Gu, Yangzuo ; Wu, Jieheng ; Gao, Jianmei ; Zhao, Xing ; He, Zhixu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c564t-4270fffa09f8d7ccab27b861589ee47d5a577ee1d5ffa2b1d348589c41b4f33a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Acute lymphocytic leukemia</topic><topic>Animals</topic><topic>Antigens</topic><topic>Antigens, CD19 - genetics</topic><topic>Antigens, CD19 - metabolism</topic><topic>CD19 antigen</topic><topic>CD20 antigen</topic><topic>CD69 antigen</topic><topic>Cell Line, Tumor</topic><topic>Cell therapy</topic><topic>Cells</topic><topic>Chimeric antigen receptor</topic><topic>Chimeric antigen receptors</topic><topic>Cloning</topic><topic>Cord blood</topic><topic>Cytotoxicity</topic><topic>Cytotoxicity, Immunologic - genetics</topic><topic>Diseases</topic><topic>Down-regulation</topic><topic>Dual targets</topic><topic>Electroporation</topic><topic>Flow cytometry</topic><topic>Graft versus host disease</topic><topic>Immunotherapy, Adoptive</topic><topic>Killer Cells, Natural</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Mice</topic><topic>mRNA</topic><topic>Natural killer cells</topic><topic>Perforin</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</topic><topic>Quantitative analysis</topic><topic>Receptors, Chimeric Antigen - metabolism</topic><topic>Relapse</topic><topic>Remission (Medicine)</topic><topic>RNA</topic><topic>RNA polymerase</topic><topic>RNA, Messenger - metabolism</topic><topic>Tumor cell lines</topic><topic>Tumors</topic><topic>Umbilical cord</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Na</creatorcontrib><creatorcontrib>Zhang, Caili</creatorcontrib><creatorcontrib>Zhang, Yingchun</creatorcontrib><creatorcontrib>Fan, Yuting</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Lin, Xiaojin</creatorcontrib><creatorcontrib>Guo, Ting</creatorcontrib><creatorcontrib>Gu, Yangzuo</creatorcontrib><creatorcontrib>Wu, Jieheng</creatorcontrib><creatorcontrib>Gao, Jianmei</creatorcontrib><creatorcontrib>Zhao, Xing</creatorcontrib><creatorcontrib>He, Zhixu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Na</au><au>Zhang, Caili</au><au>Zhang, Yingchun</au><au>Fan, Yuting</au><au>Zhang, Jing</au><au>Lin, Xiaojin</au><au>Guo, Ting</au><au>Gu, Yangzuo</au><au>Wu, Jieheng</au><au>Gao, Jianmei</au><au>Zhao, Xing</au><au>He, Zhixu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia</atitle><jtitle>Journal of translational medicine</jtitle><addtitle>J Transl Med</addtitle><date>2024-03-13</date><risdate>2024</risdate><volume>22</volume><issue>1</issue><spage>274</spage><epage>15</epage><pages>274-15</pages><artnum>274</artnum><issn>1479-5876</issn><eissn>1479-5876</eissn><abstract>Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy. However, our prior study revealed challenges in CAR-NK cells targeting CD19 antigens, as they failed to eliminate CD19
Raji cells in NSG tumor-bearing mice, noting down-regulation or loss of CD19 antigen expression in some Raji cells. In response, this study aims to enhance CD19 CAR-NK cell efficacy and mitigate the risk of tumor recurrence due to target antigen escape by developing CD19 and CD20 (CD19/CD20) dual-targeted CAR-NK cells.
Initially, mRNA encoding anti-CD19 CARs (FMC63 scFv-CD8α-4-1BB-CD3ζ) and anti-CD20 CARs (LEU16 scFv-CD8α-4-1BB-CD3ζ) was constructed via in vitro transcription. Subsequently, CD19/CD20 dual-targeted CAR-NK cells were generated through simultaneous electrotransfection of CD19/CD20 CAR mRNA into umbilical cord blood-derived NK cells (UCB-NK).
Following co-electroporation, the percentage of dual-CAR expression on NK cells was 86.4% ± 1.83%, as determined by flow cytometry. CAR expression was detectable at 8 h post-electric transfer, peaked at 24 h, and remained detectable at 96 h. CD19/CD20 dual-targeted CAR-NK cells exhibited increased specific cytotoxicity against acute lymphoblastic leukemia (ALL) cell lines (BALL-1: CD19
CD20
, REH: CD19
CD20
, Jurkat: CD19
CD20
) compared to UCB-NK, CD19 CAR-NK, and CD20 CAR-NK cells. Moreover, CD19/CD20 dual-targeted CAR-NK cells released elevated levels of perforin, IFN-γ, and IL-15. Multiple activation markers such as CD69 and cytotoxic substances were highly expressed.
The creation of CD19/CD20 dual-targeted CAR-NK cells addressed the risk of tumor escape due to antigen heterogeneity in ALL, offering efficient and safe 'off-the-shelf' cell products. These cells demonstrate efficacy in targeting CD20 and/or CD19 antigens in ALL, laying an experimental foundation for their application in ALL treatment.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38475814</pmid><doi>10.1186/s12967-024-04990-6</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1479-5876 |
ispartof | Journal of translational medicine, 2024-03, Vol.22 (1), p.274-15, Article 274 |
issn | 1479-5876 1479-5876 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_e9313db57b0742fe91ef8d45a640c2e7 |
source | PubMed (Medline); Publicly Available Content Database (Proquest) (PQ_SDU_P3) |
subjects | Acute lymphoblastic leukemia Acute lymphocytic leukemia Animals Antigens Antigens, CD19 - genetics Antigens, CD19 - metabolism CD19 antigen CD20 antigen CD69 antigen Cell Line, Tumor Cell therapy Cells Chimeric antigen receptor Chimeric antigen receptors Cloning Cord blood Cytotoxicity Cytotoxicity, Immunologic - genetics Diseases Down-regulation Dual targets Electroporation Flow cytometry Graft versus host disease Immunotherapy, Adoptive Killer Cells, Natural Leukemia Lymphatic leukemia Lymphocytes Lymphocytes T Lymphoma Medical prognosis Mice mRNA Natural killer cells Perforin Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Quantitative analysis Receptors, Chimeric Antigen - metabolism Relapse Remission (Medicine) RNA RNA polymerase RNA, Messenger - metabolism Tumor cell lines Tumors Umbilical cord γ-Interferon |
title | CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A34%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD19/CD20%20dual-targeted%20chimeric%20antigen%20receptor-engineered%20natural%20killer%20cells%20exhibit%20improved%20cytotoxicity%20against%20acute%20lymphoblastic%20leukemia&rft.jtitle=Journal%20of%20translational%20medicine&rft.au=Yang,%20Na&rft.date=2024-03-13&rft.volume=22&rft.issue=1&rft.spage=274&rft.epage=15&rft.pages=274-15&rft.artnum=274&rft.issn=1479-5876&rft.eissn=1479-5876&rft_id=info:doi/10.1186/s12967-024-04990-6&rft_dat=%3Cgale_doaj_%3EA786245159%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c564t-4270fffa09f8d7ccab27b861589ee47d5a577ee1d5ffa2b1d348589c41b4f33a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2956883055&rft_id=info:pmid/38475814&rft_galeid=A786245159&rfr_iscdi=true |